Related Experiment Videos
New lignans from Anogeissus acuminata with HIV-1 reverse transcriptase inhibitory activity
A M Rimando1, J M Pezzuto, N R Farnsworth
1Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago 60612.
Journal of Natural Products
|July 1, 1994
Summary
Anolignan A and B from Anogeissus acuminata show synergistic inhibition of HIV-1 reverse transcriptase (RT). These lignans offer potential for developing new antiviral therapies against HIV.
Area of Science:
- Natural Product Chemistry
- Virology
- Medicinal Chemistry
Background:
- Anogeissus acuminata is a plant source of bioactive compounds.
- Lignans are a class of natural products with diverse biological activities.
- HIV-1 reverse transcriptase (RT) is a key target for antiviral drug development.
Purpose of the Study:
- To isolate and identify novel lignans from Anogeissus acuminata.
- To evaluate the inhibitory activity of isolated compounds against HIV-1 RT.
- To investigate the synergistic effects of active compounds.
Main Methods:
- Bioassay-guided fractionation was employed to isolate active constituents.
- Spectroscopic methods, including 1D and 2D NMR, were used for structure elucidation.
- In vitro assays were performed to assess HIV-1 RT inhibition and cytotoxicity.
Main Results:
- Anolignan A (1) and anolignan B (3) were identified as novel dibenzylbutadiene lignans.
- Compounds 1 and 3 exhibited significant synergistic inhibitory activity against HIV-1 RT.
- Anolignan C (5) and (-)-secoisolariciresinol (10) were also isolated but showed no HIV-1 RT activity.
- Compounds 1, 3, and 5 displayed weak or no cytotoxicity against cancer cell lines.
Conclusions:
- Anolignan A and B are potent synergistic inhibitors of HIV-1 RT.
- The synergistic interaction between anolignan A and B enhances their antiviral potential.
- These findings suggest Anogeissus acuminata lignans as promising leads for novel anti-HIV drug discovery.